PDF(Pubmed)
Abstract：
Background Vernal keratoconjunctivitis (VKC) is an allergic conjunctival inflammation with severe ocular complications if left untreated. The current management regimen is plagued with adverse effects, long-term problems, and clinical relapses. Tacrolimus offers an alternative treatment option, and long-term studies are needed to determine its efficacy. Methods A two-year follow-up based study was conducted on moderate to severe VKC patients, who were prescribed tacrolimus skin ointment. The 5-5-5 exacerbation scale was used for the monitoring and grading severity of the disease. Analysis of variance (ANOVA) and intergroup comparisons were conducted on exacerbation scale scores among follow-ups. Results A significant reduction was observed in the total score of severity from baseline (203.17±102.05) to three months\' follow-up (69.94±70.54), and it kept reducing for 18 months post therapy. Similar results with statistically significant reduction were observed for all grades of the scale. The relapse rate was 5.71% within a month after therapy cessation, and none of the other patients showed relapse afterward. No significant ocular and systemic complications were observed during the study. Conclusion Tacrolimus is effective in the long-term management of VKC without the complications of conventional steroid-based therapy.
摘要：
背景：常性角膜结膜炎（VKC）是一种过敏性结膜炎症，如果不治疗，会出现严重的眼部并发症。目前的管理方案受到不良影响的困扰，长期问题,和临床复发。他克莫司提供了另一种治疗选择，需要长期研究来确定其疗效。方法对中重度VKC患者进行为期两年的随访研究，他克莫司皮肤软膏。5-5-5加重量表用于疾病的监测和分级。在随访期间对加重量表评分进行方差分析(ANOVA)和组间比较。结果从基线（203.17±102.05）到随访3个月（69.94±70.54），严重程度总分显着降低。治疗后18个月持续减少。对于所有等级的量表,观察到具有统计学显著降低的类似结果。停药后一个月内复发率为5.71%,其他患者此后均未出现复发。研究期间未观察到明显的眼部和全身并发症。结论他克莫司对VKC的长期治疗有效,且无常规激素治疗的并发症。
